Rapid Method Development and Quality Regulatory Submissions: Combining UPLC, Quality-by-Design (QbD)

Time:June 05-05, 2014

Organizer:European Pharmaceutical Review (EPR)

  • Share on Facebook
  • Tweet
  • Post to Tumblr
  • Pin it
  • Add to Pocket
  • Submit to Reddit
  • Share on LinkedIn
  • Publish on WordPress
  • Save to Pinboard
  • Send email

Method development and validation are essential parts of the pharmaceutical drug approval process. As process modifications are made and approval criteria become increasingly stringent, changes to the validated method are sometimes necessary. A Quality by Design (QbD) approach to method development uses statistical design of experiments (DoE) to generate a robust method ‘design space’. The design space defines a region in which changes to method parameters will not significantly affect the results, incorporating risk-based assessment of the final method. Rather than developing and validating a single method and proceeding through re-validation as modifications are made, a design space incorporates allowable flexibility into the method.

Tel:400-610-1188

E-mail:cphiservice@ubmsinoexpo.com

PharmaSources Customer Service